The global appetite stimulant market size was estimated at USD 1.73 billion in 2025 and is projected to reach USD 2.90 billion by 2033, growing at a CAGR of 6.76% from 2026 to 2033. The market is primarily driven by its ability to address unmet clinical needs in patients experiencing reduced appetite and unintended weight loss, which are commonly associated with chronic illnesses, aging, and post-treatment recovery conditions.
Appetite stimulants play a critical supportive role in improving overall patient outcomes, particularly during disease management and recovery phases. These therapies help enhance nutritional intake, support weight maintenance or gain, and improve strength and energy levels in patients suffering from conditions such as cancer, HIV/AIDS, chronic kidney disease, and gastrointestinal disorders. As a result, they are increasingly being integrated into broader therapeutic care plans alongside primary disease treatments.
Growing emphasis on quality of life is further increasing the importance of appetite-enhancing solutions across healthcare systems. Healthcare providers are placing greater focus not only on treating the underlying disease but also on managing secondary symptoms such as loss of appetite, fatigue, and malnutrition, which can significantly impact recovery rates and overall patient well-being.
In addition, rising healthcare expenditure globally is supporting better access to supportive care medications, including appetite stimulants. Improved insurance coverage and expanding healthcare infrastructure in emerging economies are also contributing to wider adoption of these therapies.
The market is further benefiting from a growing shift toward holistic patient care, where treatment approaches focus on comprehensive health management rather than disease-specific interventions alone. This trend is encouraging the use of appetite stimulants as part of integrated care strategies designed to improve nutritional status, enhance recovery outcomes, and support long-term patient health.
Key Market Trends & Insights
• The North America appetite stimulant market held the largest share of 40.09% of the global market in 2025. This dominant position is driven by the region’s advanced healthcare infrastructure, high awareness of supportive care therapies, and strong diagnosis rates of conditions associated with appetite loss and unintended weight reduction. The widespread availability of prescription medications, well-established clinical guidelines, and strong presence of key pharmaceutical companies further support the region’s leadership in the global market. In addition, higher healthcare spending and better access to palliative and chronic disease care contribute significantly to sustained demand across North America.
• The appetite stimulant industry in the U.S. is expected to grow significantly over the forecast period. Growth in the country is supported by the rising prevalence of chronic diseases such as cancer, HIV/AIDS, and gastrointestinal disorders, which are commonly associated with appetite suppression and cachexia. Increasing focus on improving patient quality of life, expanding geriatric population, and growing adoption of supportive care treatments are further driving market expansion. Additionally, advancements in drug development and improved access to healthcare services are expected to strengthen long-term growth prospects.
• By pharmacological class, the progestational & hormonal agents segment held the largest market share of 31.54% in 2025. This segment dominates due to the proven effectiveness of hormonal therapies in stimulating appetite and promoting weight gain in patients suffering from chronic illness-related anorexia and cachexia. These agents are widely used in clinical settings as they help regulate metabolic pathways, improve energy balance, and support nutritional recovery, making them a preferred option in supportive care treatment plans.
• By indication, the disease-related cachexia segment held the largest market share in 2025. Cachexia associated with chronic diseases such as cancer, AIDS, and advanced organ failure is a major driver of appetite stimulant usage. This condition leads to severe weight loss, muscle wasting, and reduced quality of life, creating a strong need for effective appetite-enhancing therapies. Appetite stimulants play a key role in managing symptoms, improving nutritional intake, and supporting overall patient strength during disease progression.
• By route of administration, the oral segment held the largest market share in 2025. Oral appetite stimulants are widely preferred due to their ease of administration, patient convenience, and non-invasive nature. They are readily available in multiple dosage forms, making them suitable for long-term use in both hospital and home care settings. The strong preference for oral medications in chronic disease management continues to support the dominance of this segment.
Looking for more specific insights? Customize this report to suite your business needs
Key Appetite Stimulant Company Insights
Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc (GSK), Novartis AG, Sanofi S.A., AbbVie Inc., and Teva Pharmaceutical Industries Ltd. are actively shaping the appetite stimulant market through continuous strategic investments in research and development, product innovation, and commercialization initiatives. These companies collectively play a central role in advancing supportive care therapeutics aimed at addressing appetite loss and related nutritional deficiencies across diverse patient populations.
• Pfizer Inc. and Novartis AG are focused on strengthening their appetite-enhancing therapeutic portfolios by optimizing existing drug formulations and exploring new clinical applications. Their efforts include investigating additional indications for conditions such as cancer-related cachexia, chronic illness-induced anorexia, and age-related appetite decline, thereby expanding the therapeutic value of their existing assets.
• Merck & Co., Inc. and Johnson & Johnson are concentrating on expanding clinical evidence supporting their orexigenic agents and supportive care therapies. Their strategies emphasize improving patient outcomes by enhancing nutritional intake, stabilizing body weight, and supporting recovery in patients suffering from chronic and debilitating conditions across multiple healthcare settings.
• GlaxoSmithKline plc (GSK) and Sanofi S.A. are investing in multi-modal treatment approaches that integrate appetite stimulant therapies with broader supportive care strategies. These approaches are designed to address not only appetite loss but also associated symptoms such as fatigue, weakness, and malnutrition, ultimately improving overall patient quality of life and treatment adherence.
• AbbVie Inc. leverages its expertise in hormone-based and metabolic therapies to contribute to appetite modulation treatment options. The company’s focus includes developing therapies that influence metabolic pathways and hormonal balance to support improved appetite regulation and weight management in clinical populations.
• Teva Pharmaceutical Industries Ltd. enhances its market presence through the development and distribution of cost-effective formulations of appetite-stimulating medications. Its strong global distribution network and emphasis on affordability enable broader access to supportive care treatments, particularly in cost-sensitive healthcare markets.
Collectively, these companies are driving advancements in clinical research, formulation innovation, and market accessibility. Their combined efforts continue to strengthen the global appetite stimulant market by improving treatment efficacy, expanding therapeutic applications, and enhancing patient-centric care solutions.
Key Appetite Stimulant Companies:
The following key companies have been profiled for this study on the appetite stimulant market.
• Pfizer Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• GlaxoSmithKline plc (GSK)
• Novartis AG
• Sanofi S.A.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
Grand View Research offers
√ Focused market intelligence reports on specific geographies or high-growth segments.
√ Extended forecast timelines for long-term planning.
√ Competitor Benchmarking and Supply Chain Analysis
√ Inclusion of regulatory and policy assessments.
√ Inclusion of custom data models, KPIs, or applications unique to your business
√ Specific high-impact Data Decks and Tables to support effective decision making
And much more…
Looking for a report customized to your requirements? Explore our Custom Research Offering
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)